Last reviewed · How we verify

intravenous sedation with propofol

University Hospital, Clermont-Ferrand · Phase 3 active Small molecule

Propofol acts as a GABA_A receptor agonist, enhancing the inhibitory effects of GABA in the brain.

Propofol acts as a GABA_A receptor agonist, enhancing the inhibitory effects of GABA in the brain. Used for Sedation for diagnostic and surgical procedures, Induction and maintenance of general anesthesia.

At a glance

Generic nameintravenous sedation with propofol
SponsorUniversity Hospital, Clermont-Ferrand
Drug classGABA_A receptor agonist
TargetGABA_A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

This results in sedation and hypnosis, making it useful for inducing and maintaining anesthesia. Propofol's mechanism of action is complex and involves multiple sites of action, including the GABA_A receptor, which is the primary site of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: